Fidson Healthcare Plc, a leading pharmaceutical company in Nigeria, has announced its unaudited financial results for the first quarter ended March 31, 2025, delivering a standout performance driven by substantial revenue growth across core business segments.
The Company reported a pre-tax profit of ₦4.8 billion, representing a two hundred and thirteen percent increase compared to ₦1.5 billion in the same period of 2024. Total revenue for the quarter surged to ₦35 billion, up eighty-five percent year-on-year from ₦18.8 billion, underlining strong demand and effective market execution.
The revenue growth was largely fueled by outstanding performance in the ethical and over-the-counter (OTC) product lines. Ethical product sales contributed ₦22.9 billion, while OTC product sales totaled ₦10.04 billion.
Despite a one hundred percent increase in the cost of sales to ₦22.4 billion, Fidson recorded a gross profit of ₦12.5 billion, reflecting a sixty-four percent year-on-year growth.
Administrative expenses rose by one hundred and six percent to ₦3.3 billion, and selling and distribution expenses increased by sixty-seven percent to ₦2.1 billion. Nonetheless, Fidson delivered a robust operational performance, with operating profit rising to ₦6.6 billion, an increase of one hundred and seventy-four percent from the previous year.
Fidson’s balance sheet remains solid, with total assets growing by nearly ten percent to ₦80.4 billion. Retained earnings rose by eighteen percent to close the quarter at ₦20.9 billion, supporting future reinvestment and shareholder value.
As of the close of trading on May 2, 2025, Fidson’s share price stood at ₦22.85, reflecting a year-to-date gain of forty-seven percent, signaling strong investor confidence in the Company’s direction and long-term prospects.
Commenting on the results, Dr. Fidelis Ayebae, Managing Director and CEO of Fidson Healthcare Plc, said:
“These results are a testament to our continued focus on innovation, operational excellence, and strategic expansion. We are confident in our ability to sustain this growth trajectory and deliver long-term value to all stakeholders.”
